Statements in which the resource exists.
SubjectPredicateObjectContext
pubmed-article:10999484rdf:typepubmed:Citationlld:pubmed
pubmed-article:10999484lifeskim:mentionsumls-concept:C0013030lld:lifeskim
pubmed-article:10999484lifeskim:mentionsumls-concept:C0597357lld:lifeskim
pubmed-article:10999484lifeskim:mentionsumls-concept:C0220781lld:lifeskim
pubmed-article:10999484lifeskim:mentionsumls-concept:C1883254lld:lifeskim
pubmed-article:10999484lifeskim:mentionsumls-concept:C0243076lld:lifeskim
pubmed-article:10999484lifeskim:mentionsumls-concept:C0205430lld:lifeskim
pubmed-article:10999484lifeskim:mentionsumls-concept:C0679622lld:lifeskim
pubmed-article:10999484lifeskim:mentionsumls-concept:C0205549lld:lifeskim
pubmed-article:10999484lifeskim:mentionsumls-concept:C1707689lld:lifeskim
pubmed-article:10999484lifeskim:mentionsumls-concept:C1880355lld:lifeskim
pubmed-article:10999484lifeskim:mentionsumls-concept:C0205314lld:lifeskim
pubmed-article:10999484lifeskim:mentionsumls-concept:C0243072lld:lifeskim
pubmed-article:10999484pubmed:issue18lld:pubmed
pubmed-article:10999484pubmed:dateCreated2000-12-26lld:pubmed
pubmed-article:10999484pubmed:abstractText3-Piperazinyl-3,4-dihydro-2(1H)-quinolinone derivatives (delta-lactams) were designed, synthesized, and identified as a new series of mixed dopamine D2/D4 receptor antagonists. To further the structure-activity relationship (SAR) study, 3-piperazinylindolin-2-ones (gamma-lactams) and 3-piperazinyl-3H,4H,5H-benzo[f]azepin-2-ones (epsilon-lactams) were also prepared and examined.lld:pubmed
pubmed-article:10999484pubmed:languageenglld:pubmed
pubmed-article:10999484pubmed:journalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:10999484pubmed:citationSubsetIMlld:pubmed
pubmed-article:10999484pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:10999484pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:10999484pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:10999484pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:10999484pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:10999484pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:10999484pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:10999484pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:10999484pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:10999484pubmed:statusMEDLINElld:pubmed
pubmed-article:10999484pubmed:monthSeplld:pubmed
pubmed-article:10999484pubmed:issn0960-894Xlld:pubmed
pubmed-article:10999484pubmed:authorpubmed-author:BraunJJlld:pubmed
pubmed-article:10999484pubmed:authorpubmed-author:BrodbeckRRlld:pubmed
pubmed-article:10999484pubmed:authorpubmed-author:ZhaoHHlld:pubmed
pubmed-article:10999484pubmed:authorpubmed-author:ThurkaufAAlld:pubmed
pubmed-article:10999484pubmed:authorpubmed-author:KieltykaAAlld:pubmed
pubmed-article:10999484pubmed:issnTypePrintlld:pubmed
pubmed-article:10999484pubmed:day18lld:pubmed
pubmed-article:10999484pubmed:volume10lld:pubmed
pubmed-article:10999484pubmed:ownerNLMlld:pubmed
pubmed-article:10999484pubmed:authorsCompleteYlld:pubmed
pubmed-article:10999484pubmed:pagination2119-22lld:pubmed
pubmed-article:10999484pubmed:dateRevised2006-11-15lld:pubmed
pubmed-article:10999484pubmed:meshHeadingpubmed-meshheading:10999484...lld:pubmed
pubmed-article:10999484pubmed:meshHeadingpubmed-meshheading:10999484...lld:pubmed
pubmed-article:10999484pubmed:meshHeadingpubmed-meshheading:10999484...lld:pubmed
pubmed-article:10999484pubmed:meshHeadingpubmed-meshheading:10999484...lld:pubmed
pubmed-article:10999484pubmed:meshHeadingpubmed-meshheading:10999484...lld:pubmed
pubmed-article:10999484pubmed:meshHeadingpubmed-meshheading:10999484...lld:pubmed
pubmed-article:10999484pubmed:meshHeadingpubmed-meshheading:10999484...lld:pubmed
pubmed-article:10999484pubmed:meshHeadingpubmed-meshheading:10999484...lld:pubmed
pubmed-article:10999484pubmed:meshHeadingpubmed-meshheading:10999484...lld:pubmed
pubmed-article:10999484pubmed:meshHeadingpubmed-meshheading:10999484...lld:pubmed
pubmed-article:10999484pubmed:meshHeadingpubmed-meshheading:10999484...lld:pubmed
pubmed-article:10999484pubmed:year2000lld:pubmed
pubmed-article:10999484pubmed:articleTitleDesign, synthesis, and discovery of 3-piperazinyl-3,4-dihydro-2(1H)-quinolinone derivatives: a novel series of mixed dopamine D2/D4 receptor antagonists.lld:pubmed
pubmed-article:10999484pubmed:affiliationNeurogen Corporation, Branford, CT 06405, USA. hzhao@nrgn.comlld:pubmed
pubmed-article:10999484pubmed:publicationTypeJournal Articlelld:pubmed
pubmed-article:10999484pubmed:publicationTypeComparative Studylld:pubmed
http://linkedlifedata.com/r...http://linkedlifedata.com/r...pubmed-article:10999484lld:chembl